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Objective: Left ventricular assist devices have become an established method to
bridge patients with end-stage cardiac failure to heart transplantation. Besides
infection and bleeding, thromboembolism represents one of the most serious com-
plications. We evaluated the value of microembolic signals in predicting thromboem-
bolic events for individual patients and distinctive left ventricular assist device periods.
Methods: Twenty patients (14 male) aged 23-57 years supported with the Novacor
N100 left ventricular assist device were enrolled in this study. All patients were on
effective anticoagulation, 12 patients additionally received antiplatelet therapy.
Unilateral detection of microembolic signals was performed once weekly by in-
sonation of the middle cerebral artery using transcranial Doppler sonography for 30
minutes duration. Evidence of clinically manifest thromboembolic events was based on
regular questionnaires, clinical examinations, and results of diagnostic procedures.
Results: During a cumulative follow-up of 3876 left ventricular assist device days,
44 thromboembolic complications occurred (incidence, 1.1%) in 15 out of 20 patients.
A total of 360 transcranial Doppler sonography monitorings (range, 5-34 per patient)
were performed with an overall microembolic signals prevalence of 35.3% and a
microembolic signal mean of 2.3 9.2 per examination. There was a highly significant
correlation between the individual microembolic signal activity and the respective
incidence of clinical thromboembolism (r 0.61-0.9; P .01). Patients with additional
antiplatelet treatment had significantly less thromboembolic complications (0.7%) and
lower microembolic signal prevalence (18.3%) than those without (2.8% and 65.4%,
respectively). Individual patients and left ventricular assist device months with clinical
thromboembolization could be identified using the microembolic signal activity with
moderate positive (0.37-0.7) and high negative predictive values (0.82-1.0).
Conclusions: The amount of microembolic signals, serially detected in patients with
the Novacor left ventricular assist device, is significantly associated with their
incidence of embolic complications. The high negative predictive value of micro-
embolic signals enables to identify those patients and left ventricular assist device
periods with particularly low risk of clinical thromboembolization.
Left ventricular assist devices (LVAD) are external systems implantedto support or entirely take over the mechanical function of theimpaired left ventricle.1 Technical advances have enabled for betterpatient mobility and life quality,2 allowing their use even in anoutpatient setting.3,4 Currently, LVAD are predominantly used inpatients with severe irreversible cardiac dysfunction as a bridge to
heart transplantation.5-9 Moreover, it has been shown that in a subgroup of patients,
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the temporary use of LVAD can facilitate the recovery of
the native heart to regain normalized function.10-13 The
still-widening gap between patients awaiting cardiac trans-
plantation and the number of available donor organs14,15 has
even raised the question of whether LVAD can be used as
a permanent treatment option for end-stage heart failure.3
Nevertheless, various types of complications still repre-
sent major restrictions to widespread application of LVAD.
Besides infection and bleeding, thromboembolism repre-
sents one of the most serious complications during LVAD
use.1,6,9,16,17 However, frequencies of thromboembolic
events differ greatly among individual patients and different
types of LVAD.16-20 This raises the question about etiology
and pathomechanism of LVAD-associated thromboembo-
lisms as well as their appropriate prevention. Diagnostic
tools that enable the distinguishing of patients at low risk
from those at high risk of thromboembolization may allow
for individually tailored treatment strategies and may help
to identify the subgroup of patients most suitable for per-
manent LVAD use.
During recent years, it has been recognized that micro-
embolic signals (MES) are detectable noninvasively by
transcranial Doppler sonography (TCD) in various patient
groups suffering from stroke21-23 or prone to cerebral isch-
emia.24-31 In a preliminary study on 6 patients followed by
daily TCD studies, we have reported on a significant cor-
relation between the number of MES and the incidence of
thromboembolization during the first 30 days after LVAD
implantation.32 In this paper we present results of the long-
term follow-up of 20 patients supported by the Novacor
N100 LVAD. The aim of this study was to answer the
following questions: (1) Do MES represent prognostic
markers that reflect the individual risk of clinical thrombo-
embolization? (2) Do MES correlate with type and intensity
of antithrombotic treatment?
Methods
Subjects
From 1994 to November 1998, 20 patients who underwent im-
plantation of the Novacor N100 LVAD (Baxter Healthcare Corp.,
Novacor Div., Oakland, Calif) were enrolled in this study. After
the purpose and protocol of this study was explained comprehen-
sively, all patients gave informed consent. The patients suffered
from dilated cardiomyopathy (n  11), chronic ischemic heart
disease (n  8), and postpartum cardiomyopathy (n  1). The
LVAD implantation procedure and perioperative management has
been described elsewhere.16,33 Except for patient 2 (50%-60%
stenosis of the left carotid artery), no patient had a stenosis of the
carotid arteries 50% as assessed by extracranial Doppler sonog-
raphy and/or intraarterial angiography. Coagulation abnormalities
had been excluded by laboratory investigations. A minimum of 4
repetitive TCD monitorings was required for inclusion into the
statistical analysis. Therefore, 3 further patients in whom TCD
examinations were performed once (n  2) or twice (n  1) only
during the entire LVAD period were excluded.
Antihemostatic Treatment
Postoperatively, all patients were effectively anticoagulated using
heparin (target activated partial thromboplastin time, 60-80 s).
After stabilization of the clinical situation, oral anticoagulation
using phenprocoumon was started (target International Normalized
Ratio, 2.0-3.5). Additionally, from patient 9 on, antihemostatic
treatment was supplemented by administration of platelet aggre-
gation inhibitors (330 mg ASS plus 75 mg dipyridamole 3 times
daily). Six patients were discharged from hospital while on LVAD
and were seen every other week in the outpatient clinic. In some
patients (e.g., ambulatory, long-term LVAD use) blood was drawn
only once or twice weekly to measure the coagulation status. In
these patients, attempt was made to synchronize MES-monitoring
and coagulation tests. If no blood was drawn on the day of the
TCD examination, the blood test closest to this TCD examination
was taken for further statistical analysis.
Microemboli Monitoring
Repetitive 30-minute MES monitorings were performed using a
commonly available TCD machine (TC 4040; EME/Nicolet,
Kleinostheim, Germany). The mainstem of the middle cerebral
artery was unilaterally identified through the temporal skull in a
depth of 45 to 55 mm. The first patients (Nos. 1-7) underwent TCD
monitorings using a single-channel ultrasound probe. From patient
8 on, simultaneous 2-channel MES monitorings were performed in
depths of 45-50 mm and 55-60 mm with an interchannel distance
kept at 10 mm. The sample volume was set at 10 mm. By means
of this 2-channel approach, true MES (ie, time delay of the signal
appearance in accordance with the flow direction from the proxi-
mal to the distal channel) could be distinguished from artifact
signals, e.g., due to external manipulations at the probe (ie, simul-
taneous appearance of the signal within both channels).34,35 The
probe was fixed on the head by an elastic band to maintain the
insonation position and to avoid movement artifacts. The sono-
graphical data were processed using a 128-point fast-Fourier-
transformation with a time window overlap of at least 50%. During
the entire monitoring period, an experienced investigator was
present to watch for patient movements and to detect MES acous-
tically on-line. Additionally, the MES detection software of the
TCD machine was used with a detection threshold of 7 decibels.
Off-line reanalysis of the automatically stored signals was per-
formed later by an experienced observer. Identification of MES
was in accordance with recent consensus statements.35,36 Attempt
was made to perform MES monitorings once weekly until the
endpoint (transplantation or death) was reached. In cases of se-
verely unstable clinical situations and/or reduced patient cooper-
ation, TCD examamination was postponed until appropriate con-
ditions were regained. In ambulatory patients, TCD monitorings
were performed on the days of clinical follow-up. In our pilot
series (ie, patients 1-6),32 subjects had been examined daily during
the first month on LVAD support. To avoid statistical bias, only 1
TCD examinations per week from this period was included in the
overall statistical analysis that had been randomly selected from
the daily studies.
Before each TCD examination, a standardized questionnaire
was performed to disclose clinically manifest cerebral thrombo-
embolic events (e.g., transient focal loss of vision, sensory, motor
functions or speech disturbances). Furthermore, evidence of pe-
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ripheral and cerebral thromboembolic complications was based on
the regularly screened medical records and patient files. In cases of
cerebral or peripheral thromboembolism, results of the respective
diagnostic procedures (e.g., computed tomography of the head,
angiography of the abdominal or peripheral arteries) were noted.
Statistics
All statistical analyses were done using SPSS 9.0 for Windows
(SPSS Inc., Chicago, Ill). Descriptive statistics were done using
standard parameters such as mean  standard deviation (SD), and
maximum and minimum values. For non-normally distributed
data, comparisons of 2 and more groups were performed using the
Mann-Whitney and the Kruskal-Wallis tests. Frequency distribu-
tions were statistically assessed by 2 analysis (with Yates correc-
tion if necessary). Linear regression analysis and Pearson Product
Moment test were used to evaluate correlations between 2 param-
eters. The sensitivity, specificity, and the positive (PPV) and
negative predictive values (NPV) of MES results were calculated
with respect to occurrence of thromboembolic events. Two ap-
proaches were used to calculate the predictive values. First, the
patients’ frequency of thromboembolic complications was taken as
the outcome parameter. This analysis was therefore based on the
data of 20 individuals. Secondly, the period on LVAD support was
divided by months (ie, 30-day periods) into separate units. Only if
the residue of days was 20 and at least 2 TCD examinations had
been been performed, this period was statistically included as
another LVAD month. This led to 117 months on LVAD support,
25 of which were symptomatic (ie, at least 1 embolic complica-
tion) or asymptomatic (ie, no embolism within this month). Re-
ceiver-operating characteristic (ROC) curves for MES means and
MES prevalences were analyzed and compared statistically.37
Results
Basic characteristics of the 20 patients are given in Table 1.
The mean ( SD) duration of LVAD support was 194 
104 days (range, 23-421 days). Five patients died from
multiorgan failure (n  1), recurrent thromboembolism
with bleeding (n  2), right heart (n  1), and chronic
respiratory failure (n  1). The other 15 patients reached
heart transplantation. In 84.7% of days during LVAD sup-
port, patients were effectively anticoagulated (range, 64%-
97%). During a cumulative follow-up at 3876 days on
LVAD support, 44 thromboembolic complications occurred
in 14 patients. This led to an overall incidence of 1.1 clinical
embolic events per 100 LVAD-days. Six of the 20 patients
(30%) remained asymptomatic during the entire LVAD
support. Embolic complications affected the cerebral circu-
lation in 28 (63.6%), the retinal in 5 (11.4%), and the
peripheral vessel system in 11 cases (25%). Transient symp-
toms occurred in 32 (72.7%), persisting deficits or manifest
organ damage resulted in the remaining 12 cases (27.3%).
On cranial CT, ischemic brain infarctions were observed
following 11 out of 28 (39.3%) cerebral embolic events.
Remarkably, 5 out of 6 asymptomatic patients were on
TABLE 1. Survey of the clinical characteristics and results of repetitive MES-monitoring
Basic characteristics Treatment and clinical course MES monitoring
No. Age Sex
Primary
heart
disease
Duration of
LVAD use
(d)
Effective
anticoagulation*
(%)
Antiplatelet
treatment
Embolic events
Outcome
No. of
exams
Prevalence
of MES (%)
Mean  SD
of MESn (%)
1 23 F PPCM 161 92 No 10 (6.2) HTX 24 95.8 5.5 3.8
2 53 M ICM 159 78 No 1 (0.6) HTX 20 5 0.2 0.7
3 37 M DCM 109 81 No 1 (0.9) † 16 50 2.3 3.2
4 55 M ICM 27 72 No 5 (18.5) † 4 100 60.3 63
5 35 M DCM 161 84 No 0 (0) HTX 17 64.7 1.2 1.2
6 51 M ICM 171 96 No 5 (4.4) HTX 17 94.1 4.1 3.6
7 29 M DCM 135 84 No 2 (1.5) HTX 21 81 4.3 4.7
8 26 F DCM 85 97 No 1 (1.2) HTX 9 33.3 0.8 1.4
9 43 M ICM 237 85 Yes 2 (0.9) HTX 31 6.5 0.1 0.3
10 33 M DCM 291 91 Yes 4 (1.4) HTX 31 16.1 0.5 1.8
11 34 M DCM 309 88 Yes 0 (0) HTX 34 11.8 0.2 0.5
12 47 M DCM 272 91 Yes 8 (2.9) HTX 22 36.6 1.3 2.6
13 37 F ICM 33 73 Yes 0 (0) † 5 0 0 0
14 42 F DCM 421 84 Yes 1 (0.2) HTX 23 0 0 0
15 47 M ICM 175 91 Yes 0 (0) HTX 17 41.2 1.4 2.0
16 57 M ICM 70 77 Yes 2 (2.9) † 8 75 16.6 15.0
17 34 M DCM 214 64 Yes 1 (0.5) HTX 16 25 0.5 1.0
18 38 F DCM 224 92 Yes 0 (0) HTX 14 14.3 0.1 0.4
19 51 M DCM 298 84 Yes 1 (0.3) HTX 21 14.3 0.2 0.5
20 51 M ICM 324 74 Yes 0 (0) † 10 30 0.4 0.7
F, Female; M, male; HTX, heart transplant; PPCM, postpartum cardiomyopathy; ICM, ischemic cardiomyopathy; DCM, dilated cardiomyopathy.
*Effective anticoagulation is given as the percentage of blood tests demonstrating target values as stated in the Methods section.
†Denotes death.
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antiplatelet therapy as compared with only half of the 14
symptomatic patients (P  .30, Fisher’s exact test). Thus,
patients with platelet inhibitors had a significantly lower
incidence of clinical thromboembolism (0.7%) as compared
to those patients without antiplatelet therapy (2.5%, P 
.001). In contrast, there was no statistical association be-
tween frequency of effective anticoagulation and occur-
rence of thromboembolism (P  .80).
A survey of the TCD results is also given in Table 1. A
total of 360 TCD monitorings (range, 5-34 per patient) were
performed. This led to an average examination rate of 1
TCD monitoring every 10.2 days. MES were detected in
127 examinations (35.3%), with only 2 patients (10%) re-
maining without any MES on repetitive examinations (see
Table 1). The overall mean MES number per monitoring
was 2.3  9.2 (range, 0-154). There was a significant
correlation between prevalence and mean counts of MES (r
 0.96, P  .001). We compared the 14 patients with, and
the 6 patients without, occurrence of thromboembolic com-
plications (see Table 2). Symptomatic patients had a signif-
icantly higher prevalence (38.5%) and higher mean counts
of MES (2.94) as compared with asymptomatic subjects
(25.7% and 0.53, respectively). We did not find any statis-
tical correlation between the MES activity with either the
patient’s size (r  0.04; P  .80), body mass index (r 
0.10; P  .90), or age (r  0.06, P  .80).
Linear regression analysis revealed a highly significant
correlation between the individual MES activity and the
respective incidence of clinical thromboembolism. This was
true for both mean MES counts and the individual MES
prevalence (Table 3, Fig. 1). Because patient 4 had both a
high incidence of embolic complications and extremely
high MES activity (see Table 1), analysis was significantly
influenced by this single subject. Therefore, analysis was
repeated after exclusion of this subject. The resulting cor-
relation factors were lower but still statistically significant
(Table 3). On postmortem examination, patient 4 had
extended thrombus formation at the level of the LVAD
outflow valves, which may have caused the high rate of
thromboembolic complications.
We calculated the predictive value of the patients MES
activity with respect to the individual embolic complication
rate. As MES cut-off value, we chose the median of all
average values providing groups of similar numbers. There-
fore, we analyzed the predictive value for an individual
MES mean of 0.5 per monitoring and for an individual
MES prevalence of 30%. Two outcome cut-offs were
used: (1) evidence of any thromboembolic complication (ie,
incidence 0% throughout LVAD support), distinguishing
16 symptomatic from 4 asymptomatic patients; (2) inci-
dence of thromboembolic complications 1.1% (ie,
average incidence of thromboembolism), distinguishing 12
patients with higher-than-average, from 8 patients with low-
er-than-average, complication rates. Table 4 summarizes the
results of the statistical analysis. NPV were consistently
higher (0.82-1.0) than PPV (0.36-0.7). Moreover, PPV and
NPV were higher when using the 1.1% complication rate as
the cut-off than in distinguishing patients with from those
without any embolic complication (Table 4). ROC curve
comparison did not reveal a significant difference between
the predictive value of the MES mean and the MES prev-
alence for both of the outcome dividers (P  .80). Finally,
the threshold of 0.5 MES per TCD monitoring was ap-
TABLE 3. Results of Pearson Product Moment analysis
between the MES-activity and the risk of thromboembolic
complications
Correlation
factor P value
All 20 patients included
MES
Mean 0.91 .001
Median 0.87 .001
Prevalence 0.61 .004
After exclusion of patient 4
MES
Mean 0.51 .02
Median 0.47 .03
Prevalence 0.64 .003
TABLE 2. Comparison of LVAD patients with regard to occurrence of thromboembolic complications and antiplatelet
therapy
Thromboembolic complications Antiplatelet therapy*
Yes No P value Yes No P value
No. of patients 14 6 — 12 8 —
Mean age 41.5 40.3 0.8 42.8 38.6 .80
Mean (SD) LVAD duration 189 107 204 107 0.8 239 108 126 50 .01
Prevalence of thromboembolism (%) 1.7 0 .001 0.7 2.5 .001
MES prevalence (%) 38.5 25.7 .02 18.3 65.4 .001
MES mean (SD) 2.94 10.8 0.53 1.12 .02 0.9 4.1 4.7 14.3 .001
*Antiplatelet therapy consisted of a fixed combination of acetacetylate acid (330 mg) plus dipyridamole (75 mg) given 3 times daily.
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plied to the 117 LVAD-months with respect to its predictive
value. Months with occurrence of clinical embolic events
could be predicted with moderate values for sensitivity
(52%) and PPV (0.62) but high values for specificity (91%)
and NPV (0.87).
Discussion
In a previous study on 6 patients supported with the Nova-
cor LVAD followed for 30 days, we reported on a signifi-
cant correlation between the daily MES activity and the
clinical manifestation of thromboembolism.32 In this pilot
series, both incidence of embolic complications (6.7%) and
prevalence of MES (84.1%) were high without any corre-
lation to type or intensity of antihemostatic treatment. Here,
we present our long-term results including 20 patients cu-
mulating to a follow-up of approximately 10 years on
LVAD support. In contrast to our earlier report, MES ac-
tivity was much less, with an average prevalence of 35%
and mean value of only 2.3 per TCD examination. Interest-
ingly, the incidence of thromboembolic complications has
likewise declined more than 5 times, down to 1.1 embolic
events per 100 days. Thus, the association between subclin-
ical microemboli and clinically manifest macroemboliza-
tion, although on a lower level, remains apparent. In con-
sequence, a highly significant correlation between MES
activity and risk of embolic complications was confirmed in
the present study (r  0.61-0.92, P  .01).
Clarification for the large difference with regard to mi-
cro- and macroembolization between this and our previous
study32 provides a comparison between the first 8 patients
and the following 12 patients. Whereas the latter group
received acetylsalicylic acid (330 mg) and dipyridamol (75
mg) 3 times daily in addition to anticoagulation, the former
group received anticoagulation only. MES prevalence was
more than 3 times and MES mean counts were more than 5
times higher in the group without platelet inhibitors. Simi-
larly, the incidence of embolic complications was 4 times
higher in patients without, than in the patients with, anti-
platelet treatment. This suggests that use of platelet inhibi-
tors as an adjunct to anticoagulant therapy can sufficiently
suppress the microembolic activity and thromboembolism
as well. Schmid and colleagues38 reported on significantly
less thromboembolic complications with use of platelet
inhibitors in patients with Novacor LVAD. Growing expe-
rience with this LVAD type with respect to surgical tech-
nique and postoperative management may have further con-
tributed to this positive trend.
Irrespective of its cause, the large inter-individual variabil-
ity of clinical events in our series allowed investigation of the
diagnostic value of MES over a wide range of embolic com-
plication rates (incidence, 0-18.5%). Remarkably, correlation
factors between clinical and TCD data remained significant
even after excluding the patient (No. 4) with extreme values
most favorably influencing the data. In this respect, however,
MES prevalence was more stable than average MES counts.
We further evaluated the diagnostic value of MES to identify
patients with any embolic complication or those with an inci-
dence of clinical embolism above the overall average (ie,
1.1%). Since the latter approach generated groups of similar
size, higher predictive values were provided (0.7-1) as com-
pared with the former approach (0.36-0.82). Overall, NPV of
MES appeared to be consistently higher than PPV. According
to our data, patients with average MES prevalences of 30%
or with MES means of 0.5 had a 80% likelihood not to
develop any embolic complication and a 90% likelihood to
remain below the average complication rate of 1.1%. Thus,
MES enable to identify patients with a lower-than-average risk
of thromboembolization. However, it needs to be emphasized
that this result is based on the MES profiles assessed by
repetitive and not by single TCD monitorings. Intermittent
peak counts of MES (e.g., 100 per examination) do not
“announce” incipient stroke as has been reported in other
clinical situations.39 A high-MES profile rather indicates a
mild prothrombotic state, constituting the basis on which
thrombus formation and subsequent embolism may occur. The
optimum frequency of TCD monitorings yielding reliable
MES profiles has not been defined yet. Our long-term results
demonstrate that TCD examinations every 7-10 days reveal
results as predictive and reliable as the daily measurements in
our pilot series. As this frequency appeared to be practical even
for ambulatory patients, we recommend it for clinical use in
this patient group.
Figure 1. Regression analysis between individual MES-preva-
lence (X-axis) and incidence of thromboembolic complications
(Y-axis). The symbols represent patients without (solid circle)
and with antiplatelet therapy (open triangle). For clarity, a break
was introduced to the Y-axis owing to the high incidence of
embolic complications (18.5%) of patient 4. The line represents
the regression line.
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Other issues still to be solved are mode of generation and
structural composition of the microparticles causing MES
when insonated by TCD. As has been demonstrated, cavitation
processes at the rims of prosthetic cardiac valves can cause
gaseous microbubbles and are responsible for most MES in
these patients.40 However, much lower rates of MES are de-
tectable in porcine or bovine valve prosthesis,41,42 which are
used in the Novacor LVAD. We further found a significant
association between the MES load and treatment with platelet
inhibitors. So far, reduced MES activity with antiplatelet treat-
ment has only been reported by Goertler and colleagues43 in
patients symptomatic carotid artery stenosis presumed to be of
thrombotic structure. Therefore, we believe that at least part of
microemboli detected in our Novacor patients are of solid
nature caused by microthrombi. We are currently investigating
this issue using the oxygen inhalation technique.44 Latest de-
velopments with novel algorithms of raw data analysis of the
TCD signal will allow identification of the structural compo-
sition of MES on-line in the near future.45 This may help to
approximate an ultimate goal of MES detection, which is to
noninvasively monitor the effectiveness of various antihemo-
static therapies. Thereby, individually tailored treatment strat-
egies with optimum risk-benefit ratio could be realized.
Surprisingly, still limited studies on MES detection in
LVAD patients have been published so far. Knepper and
colleagues46 reported on MES with numbers of up to 180
per minute(!) in various types of LVAD, while half of the
patients suffered from embolic complications. Roberts and
colleagues47 reported on MES detection in patients with the
Thermo Cardiosystems 1000 IP Heartmate LVAD. They
found a very low amount of MES (prevalence, 26%; mean,
0.54) and an equally low incidence of clinical thromboem-
bolization (0.1%). Recently, Potapov and colleagues48
reported an absence of MES in 5 patients supported with the
novel DeBakey LVAD, which is believed to be of low
thrombogenicity. Interestingly, their negative MES findings
were accompanied by complete absence of clinically em-
bolic events. Results of the above studies, although limited,
show a consistent trend toward enhanced MES activity in
patients with high risk of clinical embolism and vice versa.
This finding further supports our hypothesis that the amount
of MES in LVAD patients reflects their individual throm-
boembolic activity and therefore quantifies proneness to
thromboembolic complications. Thus, there is hope that
TCD monitoring could help to establish an individually
“tailored” antihemostatic treatment based on the actual and
individual risk profile. The latter may replace the current
therapeutic strategy, which is more rigid and does not suf-
ficiently account for the inter-individually heterogeneous
incidence and risk of thromboembolic complications.
Thereby, the therapeutic dilemma between thromboembo-
lisms on the one hand, and bleeding complications on the
other, could be solved.
In summary, our long-term experience with repetitive
TCD monitorings in 20 patients supported with the Novacor
LVAD underscores the diagnostic potential of MES. The
high NPV of MES enables to identify especially patients at
low risk of thromboembolic complications, which could
guide therapeutic decisions. More recently, permanent
LVAD use is now under discussion as a definitive alterna-
tive to heart transplantation.35,36 With this regard, a low
level of MES activity on repetitive TCD monitorings, indi-
cating a reduced risk of future thromboembolic complica-
tions, could become an additional selection criterion for this
specific indication in the near future. The association of
MES activity to type of antithrombotic treatment opens
further diagnostic perspectives for this clientele. We hope
the present results will encourage other groups to investi-
gate the relevance of Doppler MES in LVAD patients.
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